Pharma / Biotech

Zerbaxa ASPECT-NP Trial Demonstrated Noninferiority to Meropenem for Ventilated Nosocomial Pneumonia

ECCMID 2019: Results of the ASPECT-NP trial showed that an investigational dose of Merck’s ceftolozane-tazobactam was noninferior to meropenem in treating adults with ventilated nosocomial pneumonia.

Source link

Related posts

ESOMEPRAZOLE MAGNESIUM Capsule, Delayed Release [Aurohealth LLC]


DOK (Docusate Sodium) Capsule, Liquid Filled [REMEDYREPACK INC.]


Influenza Increases Hospitalizations for Heart Failure


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy